CTSU/ECOG E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Sponsor: Eastern Cooperative Oncology Group
Enrolling: Female Patients Only
Study Length: 12 Months
IRB Number: AAAM2902
U.S. Govt. ID: NCT01824836
Contact: Dawn Hershman, MD: 212-305-1945 / dlh23@cumc.columbia.edu
Additional Study Information: This is a cohort study looking at the effects of anastrozole (an aromatase inhibitor) on patients, and specifically at Aromatose Inhibitor Musculoskeletal Symptoms (AIMSS). The genetic predictors of AIMSS will also be evaluated. Participants will take daily anastrazole and will be followed for 12 months. The study will enroll 35 patients at Columbia University Medical Center, but 1,000 patients worldwide.
This study is closed
Investigator
Dawn Hershman, MD
Do You Qualify?
Do you have adenocarinoma of the breast? Yes No
Are you post-menopausal? Yes No
Have you previously taken aromatase inhibitors ? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Dawn Hershman, MD
dlh23@cumc.columbia.edu
212-305-1945
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE